Rituximab, bendamustine and lenalidomide in patients with aggressive B-cell lymphoma not eligible for anthracycline-based therapy or intensive salvage chemotherapy - SAKK 38/08.

Détails

ID Serval
serval:BIB_23BA18C4B4AE
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Rituximab, bendamustine and lenalidomide in patients with aggressive B-cell lymphoma not eligible for anthracycline-based therapy or intensive salvage chemotherapy - SAKK 38/08.
Périodique
British journal of haematology
Auteur(s)
Hitz F., Zucca E., Pabst T., Fischer N., Cairoli A., Samaras P., Caspar C.B., Mach N., Krasniqi F., Schmidt A., Rothermundt C., Enoiu M., Eckhardt K., Berardi Vilei S., Rondeau S., Mey U.
ISSN
1365-2141 (Electronic)
ISSN-L
0007-1048
Statut éditorial
Publié
Date de publication
07/2016
Peer-reviewed
Oui
Volume
174
Numéro
2
Pages
255-263
Langue
anglais
Notes
Publication types: Clinical Trial, Phase II ; Journal Article ; Multicenter Study
Publication Status: ppublish
Résumé
An increasing number of older patients are suffering from aggressive lymphoma. Effective and more tolerable treatment regimens are urgently needed for this growing patient population. Patients with aggressive lymphoma not eligible for anthracycline-based first-line therapy or intensive salvage regimens were treated with the rituximab-bendamustine-lenalidomide (R-BL) regimen (rituximab 375 mg/m(2)  day 1, bendamustine 70 mg/m(2)  d 1, 2, lenalidomide 10 mg d 1-21) for six cycles every 4 weeks. Forty-one patients with a median age of 75 (range 40-94) years were enrolled: 33 patients had substantial co-morbidities. 13 patients were not eligible for anthracycline-based first-line chemotherapy, 28 patients had relapsed/refractory disease. The primary endpoint, overall response, was achieved by 25 (61%) patients (95% confidence interval 45-76%). Grade ≥ 3 toxicity comprised haematological (59%), skin (15%), constitutional (15%) and neurological (12%) events. 9 patients died during trial treatment: 5 from lymphoma progression, 2 from toxicity, 2 with sudden death. After a median follow-up of 25·9 (interquartile range 20·4-31·6) months, 13 patients were still alive. Median overall survival was 14·5 months. In conclusion, R-BL can be considered a treatment option for elderly patients with treatment naïve or relapsed/refractory aggressive lymphoma not eligible for standard aggressive regimens.

Mots-clé
Adult, Aged, Aged, 80 and over, Anthracyclines/administration & dosage, Antineoplastic Combined Chemotherapy Protocols/adverse effects, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Bendamustine Hydrochloride/administration & dosage, Female, Humans, Lymphoma, B-Cell/drug therapy, Lymphoma, B-Cell/mortality, Male, Middle Aged, Remission Induction/methods, Rituximab/administration & dosage, Salvage Therapy, Survival Rate, Thalidomide/administration & dosage, Thalidomide/analogs & derivatives
Pubmed
Création de la notice
09/04/2016 16:14
Dernière modification de la notice
20/08/2019 14:01
Données d'usage